| Autor: |
Camargo CH; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil.; Faculdade de Medicina, Universidade de São Paulo, Sao Paulo 01246-902, SP, Brazil., Yamada AY; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil.; Faculdade de Medicina, Universidade de São Paulo, Sao Paulo 01246-902, SP, Brazil., Souza AR; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Lima MJC; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Cunha MPV; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Ferraro PSP; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Sacchi CT; Laboratório Estratégico, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Santos MBND; Laboratório Estratégico, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Campos KR; Laboratório Estratégico, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Tiba-Casas MR; Centro de Bacteriologia, Instituto Adolfo Lutz, Sao Paulo 01246-902, SP, Brazil., Freire MP; Faculdade de Medicina, Universidade de São Paulo, Sao Paulo 01246-902, SP, Brazil., Barretti P; Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu 18618-686, SP, Brazil. |
| Abstrakt: |
Pseudomonas aeruginosa , an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial therapy. Therefore, the in vitro evaluation of these drugs in contemporary isolates is warranted. We evaluated the antimicrobial susceptibility and genomic aspects of 119 clinical P. aeruginosa isolates from 24 different hospitals in Brazil in 2021-2022. Identification was performed via MALDI-TOF-MS, and antimicrobial susceptibility was identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing was carried out using NextSeq equipment. The most active drug was cefiderocol (100%), followed by ceftazidime-avibactam (94.1%), ceftolozane-tazobactam (92.4%), and imipenem-relebactam (81.5%). Imipenem susceptibility was detected in 59 isolates (49.6%), and the most active aminoglycoside was tobramycin, to which 99 (83.2%) isolates were susceptible. Seventy-one different sequence types (STs) were detected, including twelve new STs described herein. The acquired resistance genes bla CTX-M-2 and bla KPC-2 were identified in ten (8.4%) and two (1.7%) isolates, respectively. Several virulence genes ( exoSTUY, toxA, aprA, lasA/B, plcH ) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years. |
